Topic: individualized drug approach

Depression is a leading cause of disability worldwide, but the effectiveness of usual antidepressant treatments is still suboptimal. Rising evidence shows that depression is associated with changes in the gut microbiota. Thus, the gut-brain-interaction became a promising treatment-target for depression, even though the mechanisms underlying this bidirectional regulation are still not fully understood. To this point, all existing studies investigated the impact of modulating the gut microbiota on depressive symptoms but neglected the other way around. To address this direction, we used electroc